Physician profile
Arjun Haridas
NPI 1497146062
$13,373.63
in general payments reported to CMS, 2019-2025
56 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $906 · 2021: $3,449 · 2022: $3,210 · 2023: $1,950 · 2024: $1,550 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,030 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,030.00 |
| Education | $107.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,759.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,476.47 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $973.21 | 2019-2025 | |
| Corcept Therapeutics | $698.11 | 2019-2025 | Korlym |
| Amgen INC. | $614.23 | 2019-2025 | Evenity, Repatha, Repatha |
| Xeris Pharmaceuticals, INC. | $546.20 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $534.56 | 2020-2024 | Tirosint, Tirosint, Licart |
| Tandem Diabetes Care, INC. | $516.19 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $473.37 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $426.77 | 2021-2025 | Unithroid |
| Mannkind Corporation | $381.10 | 2020-2025 | |
| Abbvie INC. | $378.65 | 2019-2025 | |
| Antares Pharma, INC. | $377.56 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $337.22 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.00 | 2021-2023 | Jardiance |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Haridas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.